Adam Schayowitz Sells 13,832 Zymeworks Shares at $25.85 Each, Totaling $357,557
On October 10, 2026, Adam Schayowitz, EVP and Head of R&D at Zymeworks (ZYME), sold 13,832 shares at $25.85 each, totaling $357,557, according to the SEC's Form 4 filing.
Adam Schayowitz, EVP and Head of R&D at Zymeworks Inc. (ZYME), sold 13,832 shares at $25.85 each, totaling $357,557 on October 10, 2026.
Who is Adam Schayowitz and What is His Real Role at Zymeworks Inc.
Adam Schayowitz serves as Executive Vice President (EVP) and Head of Research and Development (R&D) at Zymeworks, a publicly traded biopharmaceutical company under the ticker ZYME. In this role, he is part of the executive committee, participates in strategic decisions, and oversees scientific teams responsible for discovering new therapeutic molecules. His responsibilities include setting research priorities, managing the R&D budget, and coordinating with commercial functions to align scientific projects with market objectives.
As R&D head, Mr. Schayowitz has direct access to confidential information, including clinical trial results, partnership agreements with other companies, and revenue forecasts for pipeline products. This data is typically not publicly available and can influence market perception regarding the future value of the stock. Consequently, his transactions are considered insider trades under U.S. regulations.
Transaction Details: 13,832 shares at $25.85 each
The Form 4 filed with the SEC indicates the sale occurred on October 10, 2026. The exact number of shares sold is 13,832, with each share sold at $25.85. The gross value of the transaction amounts to $357,557, calculated by multiplying the number of shares by the per-unit price. This transaction was reported in compliance with the legal obligation to disclose insider transactions within two business days of the event, as specified by the SEC's rules on Form 4 filings.
Why Insiders Sell Their Shares â Possible Reasons
A share sale by an executive may stem from several motivations, not necessarily tied to the company's future performance. Portfolio diversification is a common reason: an executive might seek to reduce exposure to a single stock, especially if a significant portion of their wealth is already invested in their employer's shares. Tax planning is another factor, as realizing capital gains or liquidating a position before the end of the fiscal year can optimize tax liability. Personal liquidity needs, such as funding real estate projects or covering private commitments, may also prompt monetizing part of the shares held.
Itâs important to note that the decision to sell does not automatically imply a negative judgment on the company's prospects. An executive might simply rebalance their assets or comply with internal governance policies, such as adhering to ownership limits. In this case, the transaction is classified as a bearish signal, but no definitive conclusion can be drawn about ZYME's stock trajectory from this single event.
How Individual Investors Track Form 4 Filings
Form 4 filings are freely accessible on the SECâs EDGAR platform. Individual investors can search by company name, ticker, or insiderâs name to retrieve full transaction details. Several online tools aggregate this data, offering email alerts or customized dashboards that filter insider buys or sells by size or frequency. Despite the availability of information, itâs crucial to remember that the data is historical and each transaction must be analyzed in context, without relying solely on volume or price.
Limitations arise because the Form 4 does not disclose personal motivations or long-term investment strategies. Additionally, filing delays, though short, can create a slight lag between the event and its public dissemination. Savvy investors combine Form 4 analysis with other sources, such as quarterly reports, press releases, and sector analyses, to form a more comprehensive view of the risks and opportunities related to the ZYME stock.
